Table of Contents
Moderna CEO Stéphane Bancel is leading the biotechnology company’s expansion of messenger RNA technology beyond COVID-19 vaccines into cancer treatments, infectious diseases, and rare conditions. Following years of skepticism and the global rollout of its COVID vaccine, the company is now navigating both scientific breakthroughs and political headwinds in the United States.
Building a Biotechnology Platform from the Ground Up
Fifteen years ago, the biotech industry focused heavily on manipulating DNA rather than unstable messenger RNA. In 2011, Bancel partnered with venture capitalist Noubar Afeyan to helm Moderna, taking a risk on an unproven technology that most scientists dismissed. Early on, the company operated in stealth mode while researchers worked to overcome two major hurdles: controlling the immune response triggered by mRNA and delivering it effectively into the correct cells.
The company eventually directed its resources toward rare diseases, infectious disease vaccines, and cancer treatments. The COVID-19 pandemic provided a major turning point, saving an estimated 2 million lives globally and generating $46 billion between 2021 and 2024. This rapid development proved the viability and speed of mRNA platforms, allowing scientists to create new vaccine candidates within weeks.
Advancements in Personalized Cancer Vaccines
In October, Moderna and Merck reported that their individualized mRNA cancer vaccine, intismeran, successfully combined with a checkpoint inhibitor to reduce the recurrence of mid- to late-stage melanoma by 42%. The vaccine is designed by sequencing a patient’s tumor and healthy cells from a biopsy, then generating a customized mRNA code targeting specific tumor markers.
Moderna is currently conducting nine clinical trials involving intismeran across various cancers, including kidney, gastric, lung, and pancreatic cancers. Academic institutions such as Memorial Sloan Kettering Cancer Center are also launching dedicated centers to further advance personalized mRNA cancer vaccines and academic research.
Navigating Political and Financial Challenges
Despite these medical milestones, Moderna has faced financial and political challenges. In 2025, the U.S. Department of Health and Human Services canceled a $766 million contract with Moderna for pandemic influenza and bird flu vaccine development under the administration of President Donald Trump. HHS Secretary Robert F. Kennedy Jr., a vaccine skeptic, and online misinformation regarding mRNA created additional hurdles for the company.
Due to declining COVID vaccine revenues and canceled government contracts, Bancel laid off 10% of the workforce and terminated several projects, including a vaccine candidate for cytomegalovirus. However, the company secured alternative funding from the Coalition for Epidemic Preparedness Innovations to advance its bird-flu vaccine, and the U.S. Food and Drug Administration ultimately approved Moderna’s seasonal flu shot in August 2026.
Bancel expects to announce late-stage results from the company’s first mRNA treatment for a rare disease by the end of the year.
